Prime Medicine, known for its goal of treating hundreds of diseases with CRISPR, says it's narrowing its focus to two. It ...

CEO Keith Gottesdiener will be replaced by Prime's CFO as the company cuts 25% of its workforce and deprioritizes its lead ...

Despite hitting a clinical “milestone,” Prime Medicine is shelving its sole clinical-stage genetic medicine. | Despite ...

Prime Medicine is eliminating 25% of its workforce in a restructuring that includes the company pivoting its prime ...

-- Prioritizing Set of High Value Programs in Core Areas of Focus; Modularity of Prime Editing Platform Expected to Allow Prime Medicine to Generate Follow-on Candidates Rapidly and Efficiently ...

-- IND and/or CTA for PM577 for Wilson’s Disease on-track for 1H 2026 -- -- Unveiled potentially best-in-class program for AATD; IND and/or CTA filing targeted for mid-2026 -- CAMBRIDGE, Mass.

Prime Medicine, Inc. CAMBRIDGE, Mass., Jan. 07, 2025 (GLOBE NEWSWIRE) -- Prime Medicine, Inc. (Nasdaq: PRME), a biotechnology company committed to delivering a new class of differentiated one-time ...

Collaboration Combines Prime Medicine’s Precise, Multiplex Gene Editing Capabilities with Bristol Myers Squibb’s Broad Expertise in Development and Commercialization of Novel Cell Therapies ...

Arguably the more significant of the two pieces of news was that partnership deal. Prime Medicine announced that it had signed a strategic research collaboration and license agreement with global ...